Lomitapide · Juxtapid

Small molecule

Also known as AEGR-733, BMS-201038

Approvedregulatory verdict

Evidence outlook

Approved: Homozygous Familial Hypercholesterolemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (3)
JP
  • Homozygous familial hypercholesterolemia
Product first approved 2016santelog.com
CA
  • JUXTAPID® (lomitapide capsules) is indicated as an adjunct to a low-fat diet and other lipid- lowering drugs, with or without LDL apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolemia (HoFH). Due to its benefit-risk profile, the prescribing of JUXTAPID should be limited to physicians experienced in the diagnosis and treatment of familial hypercholesterolemia. The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.
Product first approved 2014Health Canada
EU
  • Homozygous familial hypercholesterolaemia in adults (marketing authorisation holder now Chiesi Farmaceutici)
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Homozygous Familial Hypercholesterolemia
NCT02765841 · Aegerion Pharmaceuticals, Inc.
2016-05 – 2019-12 · Homozygous Familial Hypercholesterolemia
What this study did
NCT00943306 · Aegerion Pharmaceuticals, Inc.
2009-10-29 – 2014-12-01 · Familial Hypercholesterolemia
What this study did
Other / comorbidity
Phase 2 (5)
Homozygous Familial Hypercholesterolemia
NCT01556906 · Aegerion Pharmaceuticals, Inc.
2003-06 – 2004-02 · Homozygous Familial Hypercholesterolemia
What this study did
Other / comorbidity
NCT00559962 · Aegerion Pharmaceuticals, Inc.
2007-10 – 2008-11 · Hyperlipidemia
What this study did
NCT00474240 · Aegerion Pharmaceuticals, Inc.
2007-04 – 2008-10 · Hypercholesterolemia
What this study did
NCT00690443 · Aegerion Pharmaceuticals, Inc.
2008-05 – 2008-09 · Hypercholesterolemia
What this study did
NCT00405067 · Aegerion Pharmaceuticals, Inc.
2006-05 – 2007-01 · Hypercholesterolemia
What this study did
Phase 1 (5)
Other / comorbidity
NCT02080468 · Aegerion Pharmaceuticals, Inc.
2014-02-19 – 2014-04-24 · Healthy
What this study did
NCT02080455 · Aegerion Pharmaceuticals, Inc.
2014-01-27 – 2014-03-07 · Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
What this study did
NCT02044419 · Aegerion Pharmaceuticals, Inc.
2013-10-30 – 2013-12-23 · Healthy
What this study did
NCT01915771 · Aegerion Pharmaceuticals, Inc.
2013-07-29 – 2013-08-23 · Intra-subject Variability of Pharmacokinetics
What this study did
NCT01760187 · Aegerion Pharmaceuticals, Inc.
2012-11-07 – 2013-06-03 · Healthy Volunteer
What this study did

Competitive landscape

This drug's own stage for Homozygous Familial Hypercholesterolemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lomitapide (Juxtapid): this drugApprovedSmall moleculeMTPWeak signal
NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658)
NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16)
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3)
Evinacumab (Evkeeza)ApprovedMonoclonal antibodyANGPTL3Partial signal
NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5)
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Reliable signal
NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001
Ezetimibe (Zetia)ApprovedSmall moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Inclisiran (Leqvio)ApprovedRNA / oligonucleotidePCSK9Partial signal
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
SHR-1918Phase 3Monoclonal antibodyANGPTL3Partial signal
NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026
ZodasiranPhase 3RNA / oligonucleotideANGPTL3 gene mRNA (hepatic)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

February 2026ApprovalFDA updates Boxed Warning on Juxtapid (NDA203858)
US, FDA · FDA · Source ↗